Core Viewpoint - The frequency of control changes in listed companies is increasing, with several companies like Tian Sheng New Materials, Asia-Pacific Pharmaceutical, Jianghua Microelectronics, and Huibo Pu announcing or planning ownership changes in early 2026. The new controlling parties include private equity (PE) firms and local state-owned assets, utilizing the "agreement transfer + private placement" method for these transitions [2][3]. Group 1: Control Changes and Methods - Multiple companies are adopting the "agreement transfer + private placement" method for control changes, which allows for a smoother transition of ownership [4]. - Tian Sheng New Materials announced a control change where the actual controller Wei Lidong acquired shares through a combination of agreement transfer and private placement, with a total transaction value of 131 million yuan for 20.49 million shares [3]. - Asia-Pacific Pharmaceutical's control change involved a share transfer at a price of 8.26 yuan per share, totaling 900 million yuan, with a premium of 45.68% over the stock price before suspension [3]. Group 2: Role of Local State-Owned Assets - Local state-owned assets have also been active in acquiring stakes in various companies, committing to hold these shares for an extended period [5]. - Jianghua Microelectronics transferred 92.38 million shares to Shanghai Fuxun at a price of 20 yuan per share, totaling 1.848 billion yuan, with the new controller being the Shanghai State-owned Assets Supervision and Administration Commission [6]. - Huibo Pu's control change involves a transfer of 25.60% of shares to Baili Equipment Group for 1.175 billion yuan, with a commitment to not transfer these shares for 18 months [6]. Group 3: Implications and Opportunities - Analysts suggest that control changes can provide new development opportunities and vitality for companies, although the actual performance improvement post-change remains to be observed [2]. - The involvement of local state-owned assets is seen as a strategy to integrate industrial chains, attract quality resources, and enhance corporate governance [6][8]. - The potential for improved company fundamentals and stock price increases exists when strong industrial backgrounds and substantial shareholders inject quality assets or drive business restructuring [8].

证券代码：002370 证券简称：亚太药业 公告编号：2026-003 浙江亚太药业股份有限公司 关于控股股东一致行动人股权结构调整的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完 整，没有虚假记载、误导性陈述或者重大遗漏。 1、本次变更前，星宸投资的合伙人信息及出资情况如下： 浙江亚太药业股份有限公司（以下简称"公司"）于近日收到控 股股东一致行动人浙江星宸股权投资合伙企业（有限合伙）（以下简 称"星宸投资"）关于其股权结构调整的通知，现将有关情况公告如 下： 一、控股股东一致行动人股权结构调整的基本情况 2026 年 1 月 16 日，公司收到控股股东一致行动人星宸投资的《告 知函》，其因出资结构调整，原 LP 由安吉久恒创业投资有限公司调 整为安吉久恒创业投资有限公司和安吉数智星越股权投资合伙企业 （有限合伙）。安吉久恒创业投资有限公司和安吉数智星越股权投资 合伙企业（有限合伙）均为安吉县财政局下属企业。具体情况如下： | 序号 | 合伙人名称 | | 合伙人类别 | 认缴出资额 （万元） | 出资比例 | | --- | --- | --- | --- | --- | --- | | 1 ...

亚太药业公告称，2026年1月16日收到控股股东一致行动人星宸投资《告知函》，其因出资结构调整， 原LP由安吉久恒创业投资有限公司调整为该公司和安吉数智星越股权投资合伙企业（有限合伙），二 者均为安吉县财政局下属企业。变更前，安吉久恒创业投资有限公司认缴出资4.1亿元，占比 99.5146%；变更后，其认缴2.1亿元，占比50.9709%，安吉数智星越股权投资合伙企业（有限合伙）认 缴2亿元，占比48.5437%。此次变动不影响控股股东、实际控制人，也不影响公司治理与经营。 ...

Group 1 - The China Securities Regulatory Commission (CSRC) has launched an investigation into Tianpu Co., Ltd. for significant omissions in its stock price fluctuation announcements, reflecting the regulatory body's commitment to maintaining market stability and warning investors against speculative trading [2][7] - The CSRC and the Ministry of Finance have announced new regulations to enhance the whistleblower reward system for securities and futures violations, increasing the reward cap from 100,000 yuan to 1 million yuan, thereby encouraging the reporting of illegal activities [2][7] - In December 2025, the Consumer Price Index (CPI) showed a year-on-year increase of 0.8%, while the Producer Price Index (PPI) decreased by 1.9%, indicating mixed trends in price movements influenced by international commodity prices and domestic policies [2][7] Group 2 - The Shanghai Composite Index has risen for 16 consecutive days, surpassing 4,100 points for the first time in a decade, with total trading volume in the Shanghai and Shenzhen markets exceeding 3 trillion yuan [3][8] - Starting April 1, 2026, the export tax rebate for photovoltaic products will be canceled, and the rebate rate for battery products will be reduced from 9% to 6%, which is expected to help the industry eliminate outdated capacity and create investment opportunities in valuation recovery and new technologies [3][8] - Multiple listed companies are undergoing changes in controlling stakes, with significant transactions such as the transfer of shares in Asia-Pacific Pharmaceutical and plans for fundraising for new drug development, drawing market attention to their future strategies [3][9] Group 3 - Foreign investment is optimistic about the Chinese economy and market, with firms like Goldman Sachs and UBS predicting increases in the MSCI China Index and the CSI 300 Index, highlighting technology innovation and AI industries as core growth areas [4][9] - Copper prices have surged by 22% in a month due to factors like U.S. stockpiling and AI trends, prompting Goldman Sachs to raise its price forecast for copper in the first half of 2026 to $12,750 per ton, while maintaining a year-end forecast of $11,200 per ton [4][5][9] - Employees at Shenwan Hongyuan Futures faced a violent incident while protesting significant cuts to year-end bonuses, indicating potential challenges and restructuring within the futures industry amid salary constraints [10]

证券代码：002370 证券简称：亚太药业 公告编号：2026-002 浙江亚太药业股份有限公司 关于银行账户被冻结的进展及募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"）因与江西人可 医药科技有限公司（以下简称"人可医药"）合同纠纷，人可医药向 南昌经济技术开发区人民法院申请财产保全，冻结公司银行账户资金， 现将相关事项进展情况公告如下： - 2 - 一次债券持有人会议和 2024 年第二次临时股东大会，分别审议通过 了《关于终止可转债募集资金投资项目的议案》，募投项目终止后， 为保障投资者权益，公司将剩余的募集资金继续留存于募集资金专户， 优先用于可转债回售、可转债有条件赎回或到期赎回；可转债摘牌后， 剩余的募集资金（含利息）全部转出专户用于永久补充流动资金，届 时公司授权管理层办理相关募集资金专户销户手续，募集资金专户注 销后，公司与保荐机构、开户银行签署的募集资金监管协议随之终止， 具体内容详见 2024 年 12 月 12 日公司在指定信息披露媒体《证券时 报》和巨潮资讯网（ww ...

Group 1 - Zhejiang Apac Pharmaceutical Co., Ltd. announced the completion of the transfer of control to Xinghao Holdings, marking the end of a three-month control change process [1] - The transfer involved a share transfer at a price of 8.26 yuan per share, totaling 900 million yuan for a 14.61% stake, representing a 45.68% premium over the pre-suspension price of 5.67 yuan [1] - Apac Pharmaceutical plans to raise up to 700 million yuan through a private placement to fund new drug research and development, further consolidating Xinghao Holdings' control [1] Group 2 - Xinghao Holdings has signed a technology development contract with Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. for the domestic rights transfer of the innovative drug STC008, targeting late-stage non-small cell lung cancer [2] - The change in control signifies a new era for Apac Pharmaceutical under the leadership of Qiu Zhongxun, who is expected to integrate digital ecosystems with the company's R&D capabilities [2] - The market anticipates that Qiu Zhongxun will lead the revival and new achievements of this established pharmaceutical company [2]

Core Viewpoint - The control change at Asia-Pacific Pharmaceutical (亚太药业) has been completed, with Xinghao Holdings becoming the new controlling shareholder, holding a total of 14.61% voting rights, marking a significant transition in the company's leadership and strategic direction [1][2] Group 1: Control Change Details - Xinghao Holdings acquired 14.61% of the voting rights through a combination of direct shareholding and the transfer of voting rights from a related party [1] - The share transfer involved a total transaction amount of 900 million yuan at a price of 8.26 yuan per share, representing a premium of 45.68% over the pre-suspension price of 5.67 yuan per share [1] Group 2: Future Plans and Strategic Direction - Following the share issuance, Xinghao Holdings is expected to hold 22.38% of the company's shares, further solidifying its control [2] - The new actual controller, Qiu Zhongxun, is a prominent figure in the pharmaceutical industry, which is anticipated to enhance the company's innovation and development capabilities [2] - Asia-Pacific Pharmaceutical plans to transition from traditional chemical generics to improved new drugs and innovative drug development, supported by a fundraising effort of up to 700 million yuan for research projects [1][2]

公告显示，本次协议转让完成后，公司的控股股东由富邦集团变更为星浩控股，公司的实际控制人由宋 汉平、傅才、胡铮辉组成的管理团队变更为邱中勋。 北京商报讯（记者 丁宁）1月8日晚间，亚太药业（002370）发布公告称，公司于1月8日收到中国证券 登记结算有限责任公司出具的《证券过户登记确认书》，原控股股东协议转让股份已完成过户登记手 续。 ...

格隆汇1月8日丨亚太药业(002370.SZ)公布，收到中国证券登记结算有限责任公司出具的《证券过户登 记确认书》，公司原控股股东宁波富邦控股集团有限公司（简称"富邦集团"）及一致行动人上海汉贵投 资管理有限公司（简称"汉贵投资"）向浙江星浩控股合伙企业（有限合伙）（简称"星浩控股"）、浙江 星宸股权投资合伙企业（有限合伙）（已于2025年10月27日完成私募基金备案手续，基金编码 SBHK56，北京浙商华盈创业投资管理有限公司担任星宸投资的执行事务合伙人、基金管理人，其开立 的证券户名称为北京浙商华盈创业投资管理有限公司—浙江星宸股权投资合伙企业(有限合伙)，简 称"星宸投资"）协议转让公司股份事项已完成股份过户登记手续。 本次协议转让完成后，公司的控股股东由富邦集团变更为星浩控股，公司的实际控制人由宋汉平、傅 才、胡铮辉组成的管理团队变更为邱中勋。由于星浩控股与星宸投资签署了《一致行动人协议》《表决 权委托协议》，星宸投资将其持有的公司48,420,252股全部表决权、召集权、提名和提案权、参会权、 监督建议权及除收益权和股份转让等财产性权利之外的其他权利无条件、不可撤销地委托给星浩控股行 使，星浩控股与 ...

每经AI快讯，亚太药业1月8日晚间发布公告称，浙江亚太药业股份有限公司于2026年1月8日收到中国 证券登记结算有限责任公司出具的《证券过户登记确认书》，公司原控股股东宁波富邦控股集团有限公 司及一致行动人上海汉贵投资管理有限公司向浙江星浩控股合伙企业（有限合伙）、浙江星宸股权投资 合伙企业（有限合伙）协议转让公司股份事项已完成股份过户登记手续，本次协议转让完成后，公司的 控股股东由富邦集团变更为星浩控股，公司的实际控制人由宋汉平、傅才、胡铮辉组成的管理团队变更 为邱中勋。 每经头条（nbdtoutiao）——培训5天就考证！滑雪教练速成班乱象调查：零基础也可报名，学时还 能"注水" （记者 曾健辉） ...